A cancer vaccination may become widely accessible within the next ten years, according to the husband-and-wife duo that co-founded BioNTech, the biotechnology business that collaborated with Pfizer to produce an efficient messenger-RNA (mRNA) injection against COVID-19.
According to Professor Ozlem Tureci, "Yes, we feel that a cure for cancer, or to changing the life of cancer patients, is in our grasp," during an interview on BBC's "Sunday with Laura Kuenssberg."
Within just eight years, the cancer vaccine, which would draw on the scientific advances made during the creation of the COVID-19 shot, might be publicly accessible, according to Professor Ugur Sahin.
He informed Keunssberg, "We think that this will happen, undoubtedly, before 2030.
The goal is to create a vaccine that would teach the body to identify and combat cancer utilizing mRNA technology.
"Our goal is to use the individualized vaccine approach to ensure that patients receive a personalized, individualized vaccine right after surgery and that we induce an immune response so the patient's T-cells can screen the body for any remaining tumor cells and, ideally, eliminate them," said Sahin.
According to The New York Times, BioNTech first concentrated on creating mRNA-based technology for a patient-specific approach to cancer treatment.
Turecia explained to Keunssberg that their interest in cancer research was sparked by their time as young physicians working in cancer wards and feeling upset at not being able to help oncology patients.
According to Tureci, that work served as a "tailwind" for the COVID-19 shot development, which now "gives back" to their cancer research.
Keunssberg queried the couple over the possibility that the cancer vaccine might not be effective.
Tureci gave a "I don't think so" response. We can stimulate those killer T-cells and direct them, according to what we've learned about the immune system and what a cancer vaccine can accomplish.
According to Tureci, it is yet unclear how doctors will combine different medicinal approaches with the vaccination and what else needs to be changed to guarantee that patients are cured.
In these cancer trials, Tureci stated, "Every step and every patient we treat enables us to understand more about what we are against and how to handle that."
What is Biontech all about?
They advance individualized mRNA-based cancer immunotherapy into clinical trials and establish its own manufacturing process, the company has created an mRNA-based human therapeutic for intravenous injection.
The RNA vaccine BNT162b2 for COVID-19 infections was created by BioNTech in 2020 in collaboration with Pfizer for testing and logistics. At the time, it offered a 91% efficacy in preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine.
On December 2, 2020, the British government approved interim HMR authorization for BNT162b2 vaccinations throughout the country.
It was the first mRNA vaccine to ever receive approval. A few days later, the vaccine was given emergency permission in the United States, Canada, Switzerland, and other countries. The European Medicines Agency's strong recommendation led to the European Commission's approval of BioNTech/coronavirus Pfizer's vaccine on December 21, 2020. (EMA).
Posts
.jpeg)
.jpeg)
